Capital Impact Advisors’s Blueprint Medicines BPMC Stock Holding History

Capital Impact Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,676	Closed	-$675K	–	120
2023 Q2	$675K	Buy	10,676 +550	+5%	+$29.9K	0.74%	50
2023 Q1	$456K	Buy	10,126 +2,801	+38%	+$126K	0.56%	80
2022 Q4	$321K	Hold	7,325	–	–	0.31%	139
2022 Q3	$312K	Buy	7,325 +1,320	+22%	+$84.8K	0.31%	137
2022 Q2	$303K	Sell	6,005 -2,406	-29%	-$141K	0.28%	155
2022 Q1	$537K	Buy	8,411 +744	+10%	+$53.4K	0.39%	131
2021 Q4	$821K	Buy	+7,667	New	+$802K	0.57%	61

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Capital Impact Advisors's BPMC Position: Q3 2023 in Review

Capital Impact Advisors sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 10,676 shares — an estimated $675K sold.

Capital Impact Advisors first reported a position in BPMC in Q4 2021 and held it in 7 quarters. The position peaked at $821K in Q4 2021. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

Capital Impact Advisors reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
Capital Impact Advisors sold 10,676 Blueprint Medicines shares in Q3 2023, an estimated $675K.
Capital Impact Advisors first reported a position in Blueprint Medicines in Q4 2021 and held it in 7 quarters.
Capital Impact Advisors's Blueprint Medicines position peaked at $821K in Q4 2021.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.